9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022
9 Meters Biopharma (NASDAQ:NMTR) announced participation in the William Blair Biotech Focus Conference on July 12-13, 2022, in New York City. CEO John Temperato will engage in a fireside chat, with the session available on-demand starting July 11, 2022. The presentation will spotlight 9 Meters' pipeline, particularly vurolenatide, a long-acting GLP-1 agonist for short bowel syndrome, which recently showed positive Phase 2 results. A Phase 3 study is planned for late 2022, pending FDA meeting outcomes.
- None.
- None.
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will participate in a fireside chat at the William Blair Biotech Focus Conference taking place on July 12 - 13, 2022, in New York City. Management will also be hosting one-on-one meetings with investors.
The fireside chat will be available on-demand beginning Monday, July 11, 2022. A link to the recording will be available in the events section of the 9 Meters website.
The presentation will highlight the 9 Meters pipeline, with a focus on vurolenatide, its long-acting GLP-1 agonist for short bowel syndrome. The Company recently announced positive preliminary results from a Phase 2 study of vurolenatide in short bowel syndrome and plans to initiate a Phase 3 study as early as fourth quarter 2022, pending the outcome of an end-of-Phase 2 meeting with FDA scheduled for mid-third quarter.
About 9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. 9 Meters is developing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for SBS; larazotide, a tight junction regulator; and several near clinical-stage assets.
For more information please visit www.9meters.com or follow 9 Meters on Twitter, LinkedIn and Facebook.
Forward Looking Statement
This press release includes forward-looking statements based upon 9 Meters' current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, anticipated milestones, and any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to our ability to successfully implement our strategic plans; uncertainties associated with the clinical development and regulatory approval of product candidates, including reliance on blinded data; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the inability of 9 Meters to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs, including in light of current stock market conditions; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; intellectual property risks; the impact of COVID-19 on our operations, enrollment in and timing of clinical trials; risks related to leveraging the Company by borrowing money under the debt facility and compliance with its terms; risk of delisting from Nasdaq; reliance on collaborators; reliance on research and development partners; risks related to cybersecurity and data privacy; and risks associated with acquiring and developing additional compounds. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in 9 Meters' Annual Report on Form 10-K for the year ended December 31, 2021, and in other filings that 9 Meters has made and future filings 9 Meters will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. 9 Meters expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Corporate Contact
Al Medwar
SVP, Investor Relations & Corporate Communications
9 Meters Biopharma, Inc.
investor-relations@9meters.com
Media Contact
Veronica Eames
LifeSci Communications, LLC
veames@lifescicomms.com
203-942-4626
SOURCE: 9 Meters Biopharma, Inc.
View source version on accesswire.com:
https://www.accesswire.com/707681/9-Meters-Biopharma-to-Participate-in-the-William-Blair-Biotech-Focus-Conference-2022
FAQ
When is 9 Meters Biopharma participating in the William Blair Biotech Focus Conference?
What will be discussed at the fireside chat during the William Blair Biotech Focus Conference?
What are the recent developments regarding vurolenatide?
When will the fireside chat be available on-demand?
What is the focus of 9 Meters Biopharma?
